GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteomics International Laboratories Ltd (ASX:PIQ) » Definitions » Net Cash per Share

Proteomics International Laboratories (ASX:PIQ) Net Cash per Share : A$0.03 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Proteomics International Laboratories Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Proteomics International Laboratories's Net Cash per Share for the quarter that ended in Dec. 2023 was A$0.03.

The historical rank and industry rank for Proteomics International Laboratories's Net Cash per Share or its related term are showing as below:

ASX:PIQ' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 10   Med: 22.32   Max: 42
Current: 35

During the past 9 years, the highest Price-to-Net-Cash Ratio of Proteomics International Laboratories was 42.00. The lowest was 10.00. And the median was 22.32.

ASX:PIQ's Price-to-Net-Cash is ranked worse than
93.89% of 868 companies
in the Biotechnology industry
Industry Median: 4.08 vs ASX:PIQ: 35.00

Proteomics International Laboratories Net Cash per Share Historical Data

The historical data trend for Proteomics International Laboratories's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteomics International Laboratories Net Cash per Share Chart

Proteomics International Laboratories Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only 0.01 0.01 0.04 - 0.04

Proteomics International Laboratories Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 - 0.04 0.04 0.03

Competitive Comparison of Proteomics International Laboratories's Net Cash per Share

For the Biotechnology subindustry, Proteomics International Laboratories's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteomics International Laboratories's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteomics International Laboratories's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Proteomics International Laboratories's Price-to-Net-Cash falls into.



Proteomics International Laboratories Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Proteomics International Laboratories's Net Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as

Net Cash per Share (A: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(6.027-1.752--0.058)/120.979
=0.04

Proteomics International Laboratories's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(4.97-1.717--0.122)/122.335
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proteomics International Laboratories  (ASX:PIQ) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Proteomics International Laboratories Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Proteomics International Laboratories's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteomics International Laboratories (ASX:PIQ) Business Description

Traded in Other Exchanges
N/A
Address
6 Verdun Street, QEII Medical Centre, QQ Block, Nedlands, Perth, WA, AUS, 6009
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.

Proteomics International Laboratories (ASX:PIQ) Headlines

No Headlines